DK1096936T3 - Behandling af dyskinesi ved hjælp af mu selektive opioid antagonister - Google Patents

Behandling af dyskinesi ved hjælp af mu selektive opioid antagonister

Info

Publication number
DK1096936T3
DK1096936T3 DK99932991T DK99932991T DK1096936T3 DK 1096936 T3 DK1096936 T3 DK 1096936T3 DK 99932991 T DK99932991 T DK 99932991T DK 99932991 T DK99932991 T DK 99932991T DK 1096936 T3 DK1096936 T3 DK 1096936T3
Authority
DK
Denmark
Prior art keywords
dyskinesia
treatment
opioid antagonists
selective opioid
opioid receptor
Prior art date
Application number
DK99932991T
Other languages
Danish (da)
English (en)
Inventor
Jonathan Brotchie
Original Assignee
Motac Neuroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Motac Neuroscience Ltd filed Critical Motac Neuroscience Ltd
Application granted granted Critical
Publication of DK1096936T3 publication Critical patent/DK1096936T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Resistance Heating (AREA)
DK99932991T 1998-07-18 1999-07-16 Behandling af dyskinesi ved hjælp af mu selektive opioid antagonister DK1096936T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9815618.5A GB9815618D0 (en) 1998-07-18 1998-07-18 Treatment of dyskinesia
PCT/GB1999/002146 WO2000003715A1 (en) 1998-07-18 1999-07-16 Treatment of dyskinesia

Publications (1)

Publication Number Publication Date
DK1096936T3 true DK1096936T3 (da) 2007-07-30

Family

ID=10835727

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99932991T DK1096936T3 (da) 1998-07-18 1999-07-16 Behandling af dyskinesi ved hjælp af mu selektive opioid antagonister

Country Status (13)

Country Link
US (5) US6455536B1 (enExample)
EP (2) EP1096936B1 (enExample)
JP (2) JP2002520362A (enExample)
AT (1) ATE357917T1 (enExample)
AU (1) AU759342B2 (enExample)
CA (1) CA2338066C (enExample)
CY (1) CY1108054T1 (enExample)
DE (1) DE69935670T2 (enExample)
DK (1) DK1096936T3 (enExample)
ES (1) ES2285845T3 (enExample)
GB (1) GB9815618D0 (enExample)
PT (1) PT1096936E (enExample)
WO (1) WO2000003715A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815618D0 (en) * 1998-07-18 1998-09-16 Univ Manchester Treatment of dyskinesia
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
GB0007193D0 (en) * 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US20060177381A1 (en) * 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
AU2005286733B2 (en) * 2004-09-23 2009-11-05 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2006131545A (ja) * 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
CA2685126C (en) 2007-04-24 2015-04-14 Toray Industries, Inc. Therapeutic or prophylactic agent for dyskinesia
US8138169B2 (en) 2008-04-11 2012-03-20 Comgenrx, Inc. Combination therapy for bipolar disorder
US20100168119A1 (en) * 2008-11-05 2010-07-01 Pharmorx, Inc. Compositions and methods for minimizing or reducing agonist-induced desensitization
US9918980B2 (en) 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US10736889B2 (en) 2011-04-29 2020-08-11 Rutgers, The State University Of New Jersey Method of treating dyskinesia
EP2950799B1 (en) 2013-01-30 2019-12-04 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
CA3014943A1 (en) 2016-03-31 2017-10-05 Versi Group, Llc Delta opioid agonist, mu opioid antagonist compositions and methods for treating parkinson's disease
MX2022008554A (es) 2020-01-10 2022-08-10 Trevi Therapeutics Inc Metodos de administracion de nalbufina.
US12384197B2 (en) 2022-07-15 2025-08-12 Swimc Llc Coating material container

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390699A (en) * 1981-07-16 1983-06-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services 6-Keto-morphinans belonging to the 14-hydroxy-series
US4684620A (en) * 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
PH24752A (en) * 1987-04-16 1990-10-01 Lilly Co Eli Piperidine opioid antagonists
EP0573565B1 (en) * 1991-02-25 2000-07-19 Trustees Of Boston University Opiate receptor antagonist modulates hyperkinetic movement disorder
JPH08512129A (ja) * 1993-06-23 1996-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗常習性麻酔鎮痛活性スクリーニングのための組成物および方法並びに治療
US5473620A (en) 1993-09-21 1995-12-05 Cirrus Logic, Inc. Programmable redundancy/syndrome generator
US5464841A (en) * 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
US5597309A (en) * 1994-03-28 1997-01-28 Riess; Thomas Method and apparatus for treatment of gait problems associated with parkinson's disease
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
US5821219A (en) * 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
GB9815618D0 (en) * 1998-07-18 1998-09-16 Univ Manchester Treatment of dyskinesia

Also Published As

Publication number Publication date
AU759342B2 (en) 2003-04-10
EP1096936A1 (en) 2001-05-09
CY1108054T1 (el) 2013-09-04
DE69935670D1 (de) 2007-05-10
US20050009856A1 (en) 2005-01-13
CA2338066A1 (en) 2000-01-27
WO2000003715A1 (en) 2000-01-27
PT1096936E (pt) 2007-05-31
EP1792617A1 (en) 2007-06-06
US8198294B2 (en) 2012-06-12
GB9815618D0 (en) 1998-09-16
ATE357917T1 (de) 2007-04-15
JP2002520362A (ja) 2002-07-09
JP2011037877A (ja) 2011-02-24
AU4918099A (en) 2000-02-07
US6455536B1 (en) 2002-09-24
US20100184797A1 (en) 2010-07-22
EP1096936B1 (en) 2007-03-28
US20030060478A1 (en) 2003-03-27
US6740659B2 (en) 2004-05-25
ES2285845T3 (es) 2007-11-16
CA2338066C (en) 2009-01-27
DE69935670T2 (de) 2008-01-31
US20020137669A1 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
DK1096936T3 (da) Behandling af dyskinesi ved hjælp af mu selektive opioid antagonister
AU4926301A (en) Lpa receptor agonists and antagonists and methods of use
DE60041710D1 (de) Polycycloalkylpurine als adenosinrezeptorantagonisten
IL161074A0 (en) Lactam derivatives as antagonists for human 11cby receptors
SI1425277T1 (sl) Seäśninske spojine, aktivne kot vaniloidni receptorski antagonisti za zdravljenje boleäśine
NO983002L (no) Vitronectin-reseptor-antagonister
CY1106560T1 (el) Ανταγωνιστες υποδοχεα αδενοσινης και μεθοδοι κατασκευης και χρησης αυτων
NO20020574D0 (no) Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden
TR200103119T2 (tr) Göz kurumasının tedavisi için madde.
DK1200073T3 (da) Selektive iGluR5-receptorantagonister til behandling af migræne
WO2005021496A3 (en) Synthesis of derivatives of ginkgolide c
NO985518L (no) Morfinanderivater og medisinsk anvendelse derav
NO20015259L (no) Substituerte bisykliske heterosykler, fremgangsmåte for deres fremstilling og deres anvendelse som antifedme oghyperkolesterolemiske midler
IL163709A0 (en) Fungicidal triazolopyrimidines, methods for producing the same, use thereof for combating harmful fungiand agents containing said substances
DK1223930T3 (da) Behandling af dyskinesi
DE69718146D1 (de) At1 rezeptor antagonist zur anregung von apoptosis
DK1339398T3 (da) Behandling af motoriske fluktuationer med 5-hydroxytryptamin 1A receptoraktivitetsforstærkende forbindelser
DK1224181T3 (da) Substituerede pyrroler som antiproliferative midler til behandling af cancer
BR0007395B1 (pt) compostos de s-nitrosotióis como agentes para o tratamento de disfunções circulatórias.
BR0210678A (pt) Carbamatos de 2-heterocìclicos-1,2-etanodióis
WO2002007766A3 (en) Use of d5-dopamine receptor agonists in the manufacture of a medicament for the treatment of dyskinesia
ES1042338Y (es) Barandilla de seguridad para trabajos en la construccion.
MXPA04000364A (es) Derivados de piridin-2-il-metilamina para tratar la dependencia de opioides.
WO2004067093A3 (en) Nk1 receptor antagonists for the treatment of functional dyspepsia
IT1307108B1 (it) Macchina palissonatrice per pelli.